AstraZeneca’s Fasenra Receives EU Approval for Eosinophilic Granulomatosis with Polyangiitis
Shots:
- The EU has approved Fasenra (benralizumab) as an add-on therapy for treating r/r eosinophilic granulomatosis with polyangiitis (EGPA) in adults
- The approval was based on a P-III (MANDARA) trial assessing the safety & efficacy of Fasenra (single 30mg, SC, Q4W) vs mepolizumab (separate 100mg, SC, Q4W) for treating adults (n=140) with r/r EGPA, in ratio 1:1
- The study demonstrated remission in 60% of them (comparable to mepolizumab) and 41% vs 26% fully stopped oral corticosteroids (OCS), with safety & tolerability that aligned with the previous profiles of the drugs. Data was published in the NEJM
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
